Vyome Holdings, Inc (HIND) stock
HINDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.54+0.01 (+0.98%)
Close on Nov 17, 2026Market cap $10.84MP/E –Yield –
Vyome r&d expenses
Research and development expenses are spending on new products and technology.
Vyome's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.59M, up 422.2% year over year. For fiscal 2025 it was $588.26K, up 106.1% from the year before. Over ten years it grew -26.6% a year on average. The highest annual figure on record is $12.98M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.26K | +106.1% |
| FY2024 | Dec 31, 2024 | $285.39K | -87.7% |
| FY2023 | Dec 31, 2023 | $2.32M | -8.8% |
| FY2022 | Dec 31, 2022 | $2.54M | +7.1% |
| FY2021 | Dec 31, 2021 | $2.37M | -32.3% |
| FY2020 | Dec 31, 2020 | $3.50M | -49.3% |
| FY2019 | Dec 31, 2019 | $6.89M | -35.6% |
| FY2018 | Dec 31, 2018 | $10.70M | +0.5% |
| FY2017 | Dec 31, 2017 | $10.65M | +7.9% |
| FY2016 | Dec 31, 2016 | $9.87M | -23.9% |
| FY2015 | Dec 31, 2015 | $12.98M | +125.0% |
| FY2014 | Dec 31, 2014 | $5.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $506.72K | +532.9% |
| Q1 FY2026 | Mar 31, 2026 | $666.41K | +638.3% |
| Q4 FY2025 | Dec 31, 2025 | $378.25K | +460.1% |
| Q3 FY2025 | Sep 30, 2025 | $39.68K | -40.6% |
| Q2 FY2025 | Jun 30, 2025 | $80.06K | -79.9% |
| Q1 FY2025 | Mar 31, 2025 | $90.27K | -81.3% |
| Q4 FY2024 | Dec 31, 2024 | $67.53K | -90.9% |
| Q3 FY2024 | Sep 30, 2024 | $66.82K | -87.7% |
| Q2 FY2024 | Jun 30, 2024 | $399.00K | -31.3% |
| Q1 FY2024 | Mar 31, 2024 | $484.00K | +6.8% |
| Q4 FY2023 | Dec 31, 2023 | $739.00K | +60.0% |
| Q3 FY2023 | Sep 30, 2023 | $542.00K | -7.0% |
| Q2 FY2023 | Jun 30, 2023 | $581.00K | -22.2% |
| Q1 FY2023 | Mar 31, 2023 | $453.00K | -39.2% |
| Q4 FY2022 | Dec 31, 2022 | $462.00K | +71.1% |
| Q3 FY2022 | Sep 30, 2022 | $583.00K | -59.1% |
| Q2 FY2022 | Jun 30, 2022 | $747.00K | +625.2% |
| Q1 FY2022 | Mar 31, 2022 | $745.00K | +30.5% |
| Q4 FY2021 | Dec 31, 2021 | $270.00K | -69.3% |
| Q3 FY2021 | Sep 30, 2021 | $1.43M | +65.9% |
| Q2 FY2021 | Jun 30, 2021 | $103.00K | -77.8% |
| Q1 FY2021 | Mar 31, 2021 | $571.00K | -54.6% |
| Q4 FY2020 | Dec 31, 2020 | $879.00K | -41.1% |
| Q3 FY2020 | Sep 30, 2020 | $859.00K | -26.8% |
| Q2 FY2020 | Jun 30, 2020 | $465.00K | -74.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.26M | -48.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.49M | -36.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.17M | -50.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.79M | -46.7% |
| Q1 FY2019 | Mar 31, 2019 | $2.44M | -7.6% |
| Q4 FY2018 | Dec 31, 2018 | $2.34M | -13.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.37M | -15.4% |
| Q2 FY2018 | Jun 30, 2018 | $3.35M | +21.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.64M | +10.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.69M | +3.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.80M | +29.0% |
| Q2 FY2017 | Jun 30, 2017 | $2.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.61M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.17M | – |
See a number that looks wrong?